display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)
squamous - mNSCLC - L1 - all population
atezolizumab plus carboplatin plus paclitaxel IMpower-131 ...

Study type: